Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Thoracic Malignancies
•
Medical Oncology
•
Non-small cell lung cancer
•
MET+
Do you consider MET amplification in your first-line treatment decisions for patients with metastatic NSCLC?
Answer from: Medical Oncologist at Academic Institution
Not at present and nothing is FDA approved or NCCN guidelines. Second line or later yes, especially on a trial
Comments
Medical Oncologist at Cancer Care Specialists/Renown Oncology/UNR
Agree that currently no FDA approved agents upfron...
1337
Sign in or Register to read more
5124
Related Questions
How would you treat a patient with newly diagnosed ALK+ Stage IIIB non-small cell lung cancer (NSCLC)?
For NSCLC patients treated with neoadjuvant chemoimmunotherapy and surgery with ypN2 disease, what factors would cause you to recommend PORT?
Did NRG LU004 demonstrate safety with hypofractionated lung radiation and concurrent ICI?
Do you still offer adjuvant chemotherapy and chemoradiation for NSCLC after neoadjuvant chemoimmunotherapy?
Under what circumstances, if any, would you wait on initiating a TKI for metastatic recurrence of a Stage III NSCLC which occurred while on consolidative durvalumab to minimize pneumonitis risk?
Would you consider omission of PORT for node+ NSCLC with a positive margin in the setting of a high tumor PD-L1 score and plans for immunotherapy?
Given the results of LU002 presented at ASCO 2024, are there situations and/or patient subgroups who still derive benefit from local consolidative therapy for oligometastatic NSCLC?
How do you treat Stage IIIC T4N3 NSCLC?
Which patients with Stage II-III lung adenocarcinoma, in whom you are considering neoadjuvant chemoimmunotherapy, can you rely on liquid NGS to exclude driver mutations in lieu of repeat tissue biopsy?
How do you approach a patient with stage IIA non-small cell lung cancer who received SBRT?
Agree that currently no FDA approved agents upfron...